Accordingly, coupled with the level of protective efficacy generated with its selective recognition by naturally resistant people, Sm-TSP-2 was selected for further process development and clinical trialing as a prime schistosomiasis vaccine candidate [28,29]. The gene discussed is THBS2; the disease is schistosomiasis.